TAK-577-4005: Estimating Risk of Selected Adverse Events in Patients with Von Willebrand Disease Treated With VEYVONDI® (Vonicog Alfa; Recombinant Von Willebrand Factor)

First published 03/03/2022

Last updated 02/07/2024

EU PAS number:

EUPAS45617

Study

Finalised

Documents

Study protocol

Initial protocol

tak-577-4005-protocol-original_redact

English (1.24 MB - PDF) View document

Updated protocol

TAK-577-4005-clinical-study-protocol-redact.pdf

First published: 07/05/2024

English (1.48 MB - PDF) View document

Study results

Study report

TAK-577-4005-clinical-study-report-redact.pdf

English (914.97 KB - PDF) View document

Other information

Secondary tabs